IGC
IGC Pharma, Inc. (AMEX)
Healthcare — Biotechnology
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Price History
Fundamentals
| Market Cap | $27.50M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.23 |
| EPS (TTM) | $-0.06 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -3.90% |
| ROE | -83.34% |
| Debt/Equity | 15.13 |
| Recommendation | None |
| Analyst Target | $4.25 |
| Analysts | 2 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 33.3 |
| Beta | 0.45 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $0.50 |
| 52-Week Low | $0.24 |
| 50-Day Avg | $0.30 |
| 200-Day Avg | $0.32 |
| Avg Volume | 590.3K |
| Volume | 214.3K |
Performance Analysis
NEUTRALIGC presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:14 UTC
Back to Screener Export Report